DXC vs. RTO, CART, ALLE, MEDP, ULS, WPP, GLOB, HQY, STN, and BILI
Should you be buying DXC Technology stock or one of its competitors? The main competitors of DXC Technology include Rentokil Initial (RTO), Maplebear (CART), Allegion (ALLE), Medpace (MEDP), UL Solutions (ULS), WPP (WPP), Globant (GLOB), HealthEquity (HQY), Stantec (STN), and Bilibili (BILI). These companies are all part of the "business services" industry.
DXC Technology vs.
DXC Technology (NYSE:DXC) and Rentokil Initial (NYSE:RTO) are both computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.
DXC Technology has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Rentokil Initial has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
DXC Technology has a net margin of 0.18% compared to Rentokil Initial's net margin of 0.00%. DXC Technology's return on equity of 20.42% beat Rentokil Initial's return on equity.
In the previous week, Rentokil Initial had 23 more articles in the media than DXC Technology. MarketBeat recorded 27 mentions for Rentokil Initial and 4 mentions for DXC Technology. DXC Technology's average media sentiment score of 0.87 beat Rentokil Initial's score of 0.07 indicating that DXC Technology is being referred to more favorably in the media.
96.2% of DXC Technology shares are owned by institutional investors. Comparatively, 9.9% of Rentokil Initial shares are owned by institutional investors. 0.5% of DXC Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
DXC Technology received 407 more outperform votes than Rentokil Initial when rated by MarketBeat users. Likewise, 61.25% of users gave DXC Technology an outperform vote while only 30.77% of users gave Rentokil Initial an outperform vote.
Rentokil Initial has lower revenue, but higher earnings than DXC Technology. Rentokil Initial is trading at a lower price-to-earnings ratio than DXC Technology, indicating that it is currently the more affordable of the two stocks.
DXC Technology currently has a consensus price target of $20.88, suggesting a potential upside of 1.80%. Rentokil Initial has a consensus price target of $29.00, suggesting a potential upside of 21.77%. Given Rentokil Initial's stronger consensus rating and higher probable upside, analysts clearly believe Rentokil Initial is more favorable than DXC Technology.
Summary
DXC Technology beats Rentokil Initial on 11 of the 19 factors compared between the two stocks.
Get DXC Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
DXC Technology Competitors List
Related Companies and Tools
This page (NYSE:DXC) was last updated on 1/20/2025 by MarketBeat.com Staff